World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 29 August 2016
Main ID:  NCT02878161
Date of registration: 12/07/2016
Prospective Registration: Yes
Primary sponsor: Fen Li
Public title: Predictability Studies on the Efficacy of TNF-a Inhibitors in Chinese RA From "Real World"
Scientific title: Screening Protein Predictive of Response to Tumor Necrosis Factor-a Inhibitors Treatment in Chinese Rheumatoid Arthritis From "Real World" and Investigating Its Mechanism Through Signal Pathway
Date of first enrolment: January 2016
Target sample size: 240
Recruitment status: Enrolling by invitation
URL:  https://clinicaltrials.gov/show/NCT02878161
Study type:  Interventional
Study design:  Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science  
Phase:  Phase 4
Countries of recruitment
Contacts
Name:     Fen Li, doctor
Address: 
Telephone:
Email:
Affiliation:  Central South University
Key inclusion & exclusion criteria

Inclusion Criteria:

- signed the consents voluntarily

- age between 18-75 years old

- patients were meet the American College of Rheumatology(ACR)

- European League Against Rheumatism(EULAR) 2009 diagnostic criteria (total scores
beyond 6)

- for severe RA patients DAS28-CRP=5.1

- The participants receiving Infliximab plus Methotrexate will be invited to enroll the
study.

- The participants receiving Etanercept plus Methotrexate will be invited to enroll the
study.

- The participants receiving Adalimumab plus Methotrexate will be invited to enroll the
study.

Exclusion Criteria:

- The patient have the disease history or the disease of cardiovascular, respiratory
system, liver, gastrointestinal tract, endocrine, hematology, neurology or
psychiatric disturbance, and investigator believe that there are some risks for
patients with these disease history or disease when use study drugs, or these disease
history or disease will disturb the interpret of data

- Patients with cancer in situ or exist the possibility of cancer malignancies

- Basically or completely loss of mobility, lack self-care ability, such as rely on a
wheelchair or bed-ridden .

- Experimental examination display any of the following:

Aspartate aminotransferase or alanine aminotransferase>1.5 times of the upper limit of the
normal value Total bilirubin>1.5 times of the upper limit of the normal value Total white
blood cells <2500 cells/L absolute neutrophil count <1200 cells/L lymphocyte count <750
cells/L platelet<100000/L

- Patients with symptomatic herpes simplex

- Latent tuberculosis signal (PPD+++ OR T-SPOT>5 )

- Positive result of the hepatitis B virus (HBV):

HBsAg + Or HBeAg + Or HBeAg + Or HBcAb + Or HBV DNA +

- hepatitis C virus(HCV)+ or HCV RNA +

- HIV infection or HIV+

- 1 months before join the group, from a clinical point of view,patients have a serious
infection caused by the virus, bacteria, fungi, or parasites

- Pregnancy ? location ?prepare for conceive in one years or there is risk to
impregnate their partners

- Patients received any biological therapies for 6 months, or participated any other
clinical trials of new drugs

- A history of drug allergy

- A history of heavy drink

- vaccinate the live vaccine recently



Age minimum: 18 Years
Age maximum: 75 Years
Gender: Both
Health Condition(s) or Problem(s) studied
Rheumatoid Arthritis
Intervention(s)
Biological: adalimumab
Biological: etanercept
Biological: infliximab
Drug: Glucocorticoids (permitted,not necessary)
Drug: leflunomide (permitted, not necessary)
Drug: methotrexate(necessary)
Drug: NSAIDs (permitted,not necessary)
Primary Outcome(s)
EULAR (European League Against Rheumatism) response will be assessed among patients of 3 groups [Time Frame: Baseline, Weeks 14]
Secondary Outcome(s)
The changes of Interest proteins with different EULAR response will be assessed among patients of 3 group. [Time Frame: Baseline, Weeks 14]
The changes of TNF level with different EULAR response will be assessed among patients of 3 groups. [Time Frame: Baseline, Weeks 14]
The SNP (Single nucleotide polymorphism) of gene about TNF with different EULAR response will be assessed among patients of 3 groups. [Time Frame: Weeks 14]
The SNP of gene about interest proteins with different EULAR response will be assessed among patients of 3 groups. [Time Frame: Weeks 14]
Secondary ID(s)
XYEYY-GZ81571599-20160118-1
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history